Patent No. EP3861346 (titled "Biomarkers For A Therapy Comprising A Sorafenib Compound") was filed by Eisai R&D Management on Oct 2, 2019. The application was issued on Jan 8, 2025.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents